Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

[25] In view of these data, imatinib has become the first-line treatment for patients presenting with advanced GIST. Since the 800 mg dose causes more pronounced toxic effects but equivalent ...

Management trends and outcomes of appendiceal cancers: A National Cancer Database study. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

Bezuclastinib plus sunitinib showed favorable safety and efficacy in GIST, outperforming sunitinib alone in phase 3 Peak ...

A multidisciplinary approach is crucial for managing GIST, involving surgical, medical, and potentially targeted therapies. For patients with gastrointestinal stromal tumors with liver metastases, ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

GSK acquires IDRx for $1 billion upfront, with $150M milestone payments; gains lead molecule IDRX-42 for gastrointestinal stromal tumors. IDRX-42 shows 53% ORR in 1 prior therapy line, targeting ...

The tyrosine kinase inhibitor (TKI) is designed to be a first- and second-line therapy for gastrointestinal stromal tumors (GIST) by hitting all key KIT mutations, something that gives the asset ...

Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) IDRX-42 offers potential to address all key KIT ...